IL294344B1 - Methods for treating and/or preventing major cardiovascular events (MACE) with a combination of a BET bromodomain inhibitor and a dipeptidyl peptidase 4 inhibitor - Google Patents

Methods for treating and/or preventing major cardiovascular events (MACE) with a combination of a BET bromodomain inhibitor and a dipeptidyl peptidase 4 inhibitor

Info

Publication number
IL294344B1
IL294344B1 IL294344A IL29434422A IL294344B1 IL 294344 B1 IL294344 B1 IL 294344B1 IL 294344 A IL294344 A IL 294344A IL 29434422 A IL29434422 A IL 29434422A IL 294344 B1 IL294344 B1 IL 294344B1
Authority
IL
Israel
Prior art keywords
inhibitor
mace
prevention
treatment
methods
Prior art date
Application number
IL294344A
Other languages
English (en)
Hebrew (he)
Other versions
IL294344A (en
Original Assignee
Resverlogix Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Resverlogix Corp filed Critical Resverlogix Corp
Publication of IL294344A publication Critical patent/IL294344A/en
Publication of IL294344B1 publication Critical patent/IL294344B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Cosmetics (AREA)
  • Detergent Compositions (AREA)
  • Paper (AREA)
IL294344A 2020-01-08 2022-06-27 Methods for treating and/or preventing major cardiovascular events (MACE) with a combination of a BET bromodomain inhibitor and a dipeptidyl peptidase 4 inhibitor IL294344B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062958474P 2020-01-08 2020-01-08
PCT/IB2021/000006 WO2021140418A1 (en) 2020-01-08 2021-01-07 Methods of treatment and/or prevention of major adverse cardiovascular events (mace) with a combination of a bet bromodomain inhibitor and a dipeptidyl peptidase 4 inhibitor

Publications (2)

Publication Number Publication Date
IL294344A IL294344A (en) 2022-08-01
IL294344B1 true IL294344B1 (en) 2026-03-01

Family

ID=76788523

Family Applications (1)

Application Number Title Priority Date Filing Date
IL294344A IL294344B1 (en) 2020-01-08 2022-06-27 Methods for treating and/or preventing major cardiovascular events (MACE) with a combination of a BET bromodomain inhibitor and a dipeptidyl peptidase 4 inhibitor

Country Status (9)

Country Link
US (1) US20230241064A1 (https=)
EP (1) EP4087575A4 (https=)
JP (1) JP7763761B2 (https=)
KR (1) KR20220124736A (https=)
CN (1) CN115003306A (https=)
CA (1) CA3164933A1 (https=)
IL (1) IL294344B1 (https=)
TW (1) TWI882058B (https=)
WO (1) WO2021140418A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114650824A (zh) 2019-11-05 2022-06-21 雷斯韦洛吉克斯公司 用bet溴结构域抑制剂和钠依赖性葡萄糖转运蛋白2抑制剂的组合治疗和/或预防主要不良心血管事件(mace)的方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2118074E (pt) * 2007-02-01 2014-03-20 Resverlogix Corp Compostos para a prevenção e tratamento de doenças cardiovasculares
MX2011009852A (es) * 2009-03-27 2011-09-29 Bristol Myers Squibb Co Metodos para prevenir episodios cardiovasculares adversos mayores con inhibidores de dipeptidil peptidasa iv.
AR083878A1 (es) * 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
HK1219434A1 (zh) * 2013-08-21 2017-04-07 Resverlogix Corp. 用於加速斑块消退的组合物和治疗方法
AU2014310371A1 (en) * 2013-08-21 2016-03-10 Resverlogix Corp. Compositions and therapeutic methods for accelerated plaque regression
WO2016011335A1 (en) * 2014-07-17 2016-01-21 Jerome Schentag Activation of the endogenous ileal brake hormone pathway for organ regeneration and related compositions, methods of treatment, diagnostics, and regulatory systems
US20190031774A1 (en) * 2017-06-09 2019-01-31 Sanofi Biotechnology Methods for treating hyperlipidemia in diabetic patients by administering a pcsk9 inhibitor
CN109824608B (zh) * 2019-03-15 2022-06-21 深圳晶泰科技有限公司 一种Apabetalone晶型及其制备方法

Also Published As

Publication number Publication date
WO2021140418A1 (en) 2021-07-15
JP7763761B2 (ja) 2025-11-04
CA3164933A1 (en) 2021-07-15
EP4087575A4 (en) 2024-02-28
CN115003306A (zh) 2022-09-02
JP2023509186A (ja) 2023-03-07
KR20220124736A (ko) 2022-09-14
IL294344A (en) 2022-08-01
US20230241064A1 (en) 2023-08-03
TW202140019A (zh) 2021-11-01
TWI882058B (zh) 2025-05-01
EP4087575A1 (en) 2022-11-16

Similar Documents

Publication Publication Date Title
LT4129989T (lt) Nitrilo darinys, kuris veikia kaip dipeptidilpeptidazės 1 inhibitorius ir jo panaudojimas
AU2022300368A1 (en) Erk1/2 and shp2 inhibitors combination therapy
DK4054584T3 (en) Methods of treatment and/or prevention of major adverse cardiovascular events (MACE) with a combination of a BET bromodomain inhibitor and a sodium dependent glucose transport 2 inhibitor
EP4469449A4 (en) PARP1 INHIBITORS AND THEIR USES
IL311376A (en) AZETIDINE AND PYRROLIDINE PARP1 INHIBITORS AND USES
IL320829A (en) PARP1 inhibitors and their uses
IL294344B1 (en) Methods for treating and/or preventing major cardiovascular events (MACE) with a combination of a BET bromodomain inhibitor and a dipeptidyl peptidase 4 inhibitor
LT4355749T (lt) Tricikliniai parp1 inhibitoriai ir jų panaudojimo būdai
PL372398A1 (en) Use of il-18 inhibitors for the treatment and/or prevention of peripheral vascular diseases
PL4094763T3 (pl) Związek do stosowania w zapobieganiu i/lub leczeniu stanu wywołanego lub związanego z koronawirusem
YU82602A (sh) Korišćenje il-18 inhibitora za lečenje i/ili prevenciju ateroskleroze
SG11202107720UA (en) Cnx/erp57 inhibitor for use in the treatment or prevention of cancer
PL4313010T3 (pl) Związki do zastosowania w leczeniu i profilaktyce covid-19
TW200716145A (en) Use of LGG in the manufacture of a medicament for the prevention or treatment of respiratory allergies
HK40076178A (en) Methods of treatment and/or prevention of major adverse cardiovascular events (mace) with a combination of a bet bromodomain inhibitor and a dipeptidyl peptidase 4 inhibitor
IL312886A (en) Combined treatment that includes a Pegfer inhibitor and a Kras inhibitor
IL309243A (en) Radioimmunoconjugates and combination therapy with barrier surveillance
MX2022002413A (es) Combinaciones de inhibidores de mek con inhibidores de endonucleasas cap-dependiente.
EP4178359A4 (en) COMBINATION THERAPIES FOR THE TREATMENT AND PREVENTION OF BIOFILMS
HK40113727A (en) Methods for the prevention and treatment of synucleinopathies
IL326744A (en) Treatment and prevention of cerebral atrophy
MX2025012357A (es) Uso de milvexian en el tratamiento y prevencion de afecciones tromboticas en pacientes con enfermedad cardiovascular o cerebrovascular
IL325938A (en) Combination therapy including BTK inhibitor and BELUMOSUDIL
CA3294498A1 (en) Methods for the treatment and prevention of gpp
HK40118666A (en) Psma-targeted radiopharmaceuticals and checkpoint inhibitor combination therapy